WALTHAM, Mass., Jan. 12, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that cancer drug development experts Nicole Onetto, M.D., Senior Vice President and Chief Medical Officer of ZymoGenetics, Inc., and Eric K. Rowinsky, M.D., Executive Vice President and Chief Medical Officer of ImClone Systems, Inc., a wholly-owned subsidiary of Eli Lilly and Company, have joined the Board of Directors of Symphony ViDA, Inc. Symphony ViDA is a drug development company established in October 2008 by Symphony Capital Partners, in collaboration with OXiGENE, to fund and accelerate the development of OXi4503 for oncology and ZYBRESTAT(tm) for ophthalmology. In addition to joining the Symphony ViDA Board, Drs. Onetto and Rowinsky will serve as advisors to the Symphony ViDA Development Committee and the ZYBRESTAT Advisory Committee, which oversee the development of OXi4503 and ZYBRESTAT for ophthalmology as well as ZYBRESTAT for oncology.
